Apontis Pharma AG (XTER:APPH) Debt-to-Equity : 0.20 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Apontis Pharma AG Debt-to-Equity?

Apontis Pharma AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.02 Mil. Apontis Pharma AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Apontis Pharma AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €30.26 Mil. Apontis Pharma AG's debt to equity for the quarter that ended in Dec. 2023 was 0.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Apontis Pharma AG's Debt-to-Equity or its related term are showing as below:

XTER:APPH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.2 Med: 0.2 Max: 0.2
Current: 0.2

During the past 6 years, the highest Debt-to-Equity Ratio of Apontis Pharma AG was 0.20. The lowest was 0.20. And the median was 0.20.

XTER:APPH's Debt-to-Equity is ranked better than
59.53% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs XTER:APPH: 0.20

Apontis Pharma AG Debt-to-Equity Historical Data

The historical data trend for Apontis Pharma AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apontis Pharma AG Debt-to-Equity Chart

Apontis Pharma AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.20

Apontis Pharma AG Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial				-	-	-	-	0.20

Competitive Comparison of Apontis Pharma AG's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apontis Pharma AG's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Apontis Pharma AG's Debt-to-Equity falls into.

Apontis Pharma AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Apontis Pharma AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.02	+	0)	/	30.263
	=	0.20

Apontis Pharma AG's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.02	+	0)	/	30.263
	=	0.20

Apontis Pharma AG (XTER:APPH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Apontis Pharma AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Apontis Pharma AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Apontis Pharma AG (XTER:APPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Alfred-Nobel-Strabe 10, Monheim, BY, DEU, 40789

Website

https://www.apontis-pharma.de

Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases.

Executives

Karlheinz Gast	Board of Directors
Thomas Milz	Board of Directors

Apontis Pharma AG (XTER:APPH) Headlines

No Headlines